Boston Scientific's Taxus Element
This article was originally published in The Gray Sheet
Executive Summary
Third-generation paclitaxel-eluting coronary stent system will launch in Europe in June following receipt of CE mark approval, announced May 12. The system incorporates a platinum chromium alloy, innovative stent design and advanced catheter delivery system, and includes a specific indication for treatment of diabetic patients, the firm notes. Boston Scientific expects U.S. approval in mid-2011 (1"The Gray Sheet" March 22, 2010)